RenovoRx (RNXT) LD Micro Invitational XV 2025 Conference summary

Recent advancements and commercialization

• Announced early commercialization of a new cancer therapy platform, Trans-Arterial Micro-Perfusion (TAMP), ahead of schedule.

• Received first purchase orders for the FDA-approved RenovoCath device in early 2024, with initial revenues recognized.

• Commercialization driven by strong physician demand and new reimbursement codes, enabling sales without a large sales force.

• Targeting a $400 million annualized market opportunity in the initial phase, primarily in pancreatic cancer.

• Commercialization efforts are running in parallel with ongoing phase III clinical trials.

Technology and clinical impact

• TAMP enables direct delivery of chemotherapy to tumors, increasing local drug concentration by up to 100-fold while reducing systemic toxicity by 50-65%.

• Outpatient procedure with minimal training required for physicians, making adoption easier and reducing costs.

• Demonstrated significant reduction in adverse events and improved patient quality of life compared to standard chemotherapy.

• Applicable to a range of solid tumors beyond pancreatic cancer, including bile duct, lung, and brain cancers.

• Eight patents issued covering device design and the TAMP platform.

Clinical trial progress and results

• Phase III TIGeR-PaC trial is ongoing, studying RenovoCath with gemcitabine in locally advanced pancreatic cancer.

• First interim analysis in 2023 showed a six-month survival benefit and a 65% reduction in toxicities.

• Second interim analysis and full enrollment expected in 2024, with final data anticipated by end of 2025.

• Standard of care offers 15.5 months survival; trial data suggests potential to extend this to nearly two years.

• Quality of life improvements noted, with patients resuming normal activities soon after treatment.